About AHP

Acute hepatic porphyria (AHP) is a rare genetic disease characterized by debilitating, potentially life-threatening attacks1,2

There are 4 types of AHP1,3

Most common
Chart showing the 4 types of AHP ranging from most to least common
Extremely rare
  • Acute Intermittent Porphyria (AIP)~80% of all AHP cases are AIP1
  • Variegate Porphyria (VP)
  • Hereditary Coproporphyria (HCP)
  • ALAD-Deficiency Porphyria (ADP)

ALAD, delta-aminolevulinic acid dehydratase

AHP attacks can be severe, unpredictable, and progressive1

  • AHP can affect anyone, but is most commonly seen in women of childbearing age3
  • Attacks generally last 3 to 7 days, but recovery can take longer1
  • Severe attacks can progress to respiratory failure or paralysis, leading to temporary or permanent disability2,4
  • Some patients with AHP may develop long-term complications, such as chronic kidney disease (CKD), hepatocellular carcinoma (HCC), and hypertension4

Common signs and symptoms of an AHP attack2,5,6


Plus icon

Nervous System5,6

  • Nausea/Vomiting
  • Constipation
  • Tachycardia
  • Systemic arterial hypertension

Nervous System2,5,6

  • Seizures
  • Anxiety
  • Mental status changes

Nervous System5,6

  • Limb weakness
    or pain
  • Peripheral neuropathy


  • Skin lesions on
    sun-exposed areas (Cutaneous symptoms primarily occur in HCP and VP.)

Common AHP Symptoms6,7

  • Hyponatremia
  • Dark, reddish urine

AHP=acute hepatic porphyria; HCP=hereditary coproporphyria; VP=variegate porphyria.

>90% of patients report abdominal pain during AHP attacks5

AHP can go undiagnosed for many years3,10

Because of overlapping symptoms, patients with AHP are often misdiagnosed with other diseases such as5,8,9:

Icon of intestines

Gastrointestinal disorders

  • Acute gastroenteritis
  • with vomiting
  • Irritable bowel syndrome (IBS)
  • Hepatitis

Gynecological disorder icon

Gynecological disorder

  • Endometriosis

Icon of a brain

Neurological/​neuropsychiatric disorders

  • Fibromyalgia
  • Guillain-Barré syndrome
  • Psychosis

Scalpel icon

Acute abdomen conditions

  • Appendicitis
  • Cholecystitis
  • Peritonitis
  • Pancreatitis
  • Intestinal occlusion

Explore the journeys of real AHP patients on GIVLAARI

Every patient with AHP has a unique story to tell. Discover the journeys to diagnosis and beyond for three real patients with AHP.

See Their Stories

References: 1. Simon A, Pompilus F, Querbes W, et al. Patient. 2018;11:527-537. 2. Puy H, Gouya L, Deybach JC. Lancet. 2010;375:924-937. 3. Bissell DM, Anderson KE, Bonkovsky HL. N Engl J Med. 2017;377:862-872. 4. Neeleman RA, Wagenmakers MAEM, Koole-Lesuis RH, et al. J Inherit Metab Dis. 2018;41:809-817. 5. Ventura P, Cappellini MD, Biolcati G, Guida CC, Rocchi E; Gruppo Italiano Porfiria (GrIP). Eur J Intern Med. 2014;25:497-505. 6. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Ann Intern Med. 2005;142:439-451. 7. Balwani M, Wang B, Anderson KE, et al; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Hepatology. 2017;66:1314-1322. 8. Ko JJ, Murray S, Merkel M, et al. Poster presented at: American College of Gastroenterology Annual Scientific Meeting; October 5-10, 2018; Philadelphia, PA. 9. Alfadhel M, Saleh N, Alenazi H, Baffoe-Bonnie H. Neuropsychiatr Dis Treat. 2014;10:2135-2137. 10. Anderson, KE. Mol Genet Metab. 2019;128:219-227.   




GIVLAARI® (givosiran) is contraindicated in patients with known severe hypersensitivity to givosiran. Reactions have included anaphylaxis.

Anaphylactic Reaction

Anaphylaxis has occurred with GIVLAARI treatment (<1% of patients in clinical trials). Ensure that medical support is available to appropriately manage anaphylactic reactions when administering GIVLAARI. Monitor for signs and symptoms of anaphylaxis. If anaphylaxis occurs, immediately discontinue administration of GIVLAARI and institute appropriate medical treatment.

Hepatic Toxicity

Transaminase elevations (ALT) of at least 3 times the upper limit of normal (ULN) were observed in 15% of patients receiving GIVLAARI in the placebo-controlled trial. Transaminase elevations primarily occurred between 3 to 5 months following initiation of treatment.

Measure liver function tests prior to initiating treatment with GIVLAARI, repeat every month during the first 6 months of treatment, and as clinically indicated thereafter. Interrupt or discontinue treatment with GIVLAARI for severe or clinically significant transaminase elevations. In patients who have dose interruption and subsequent improvement, reduce the dose to 1.25 mg/kg once monthly. The dose may be increased to the recommended dose of 2.5 mg/kg once monthly if there is no recurrence of severe or clinically significant transaminase elevations at the 1.25 mg/kg dose.

Renal Toxicity

Increases in serum creatinine levels and decreases in estimated glomerular filtration rate (eGFR) have been reported during treatment with GIVLAARI. In the placebo-controlled study, 15% of patients receiving GIVLAARI experienced a renally-related adverse reaction. The median increase in creatinine at Month 3 was 0.07 mg/dL. Monitor renal function during treatment with GIVLAARI as clinically indicated.

Injection Site Reactions

Injection site reactions were reported in 25% of patients receiving GIVLAARI in the placebo-controlled trial. Symptoms included erythema, pain, pruritus, rash, discoloration, or swelling around the injection site. One (2%) patient experienced a single, transient, recall reaction of erythema at a prior injection site with a subsequent dose administration.

Blood Homocysteine Increased

Increases in blood homocysteine levels have occurred in patients receiving GIVLAARI. In the ENVISION study, during the open label extension, adverse reactions of blood homocysteine increased were reported in 15 of 93 (16%) patients treated with GIVLAARI. Measure blood homocysteine levels prior to initiating treatment and monitor for changes during treatment with GIVLAARI. In patients with elevated blood homocysteine levels, assess folate, vitamins B12 and B6. Consider treatment with a supplement containing vitamin B6 (as monotherapy or a multivitamin preparation).

Drug Interactions

Concomitant use of GIVLAARI increases the concentration of CYP1A2 or CYP2D6 substrates, which may increase adverse reactions of these substrates. Avoid concomitant use of GIVLAARI with CYP1A2 or CYP2D6 substrates for which minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP1A2 or CYP2D6 substrate dosage in accordance with approved product labeling.

Adverse Reactions

The most common adverse reactions that occurred in patients receiving GIVLAARI were nausea (27%) and injection site reactions (25%).


GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).

For additional information about GIVLAARI, please see full Prescribing Information.